Larkberget FCO/Dettes

Que fait Larkberget ? Larkberget AB, trading under the ticker LARK.ST, is a biotechnology company based in Lidingoe, Sweden. The company, which is listed on the Stockholm Stock Exchange, went public through an IPO on May 25, 2015. Larkberget AB operates within the health care sector, specifically in the biotechnology industry. The company's website is https://combigene.com/. According to the provided information, Larkberget AB is engaged in the development of new treatments for neurological diseases. The firm's platform involves the use of gene therapy vectors to deliver combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. These vectors are designed for the treatment of neurological and psychiatric diseases in both humans and animals. The company focuses on developing an epilepsy treatment using an adeno-associated virus (AAV) vector that carries transgenes for the neurotransmitter NPY and its receptor, the G protein-coupled receptor Y2. The company's headquarters are located in Lidingoe, near Stockholm. Larkberget est l'une des entreprises les plus populaires sur Eulerpool.